Presentations


Xbrane Company Presentation February 2022

Xbrane Company Presentation

Press Releases

22 Jul 2022

Xbrane Biopharma releases interim report for January – June 2022

20 Jul 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2022 on July 22, 2022

04 Jul 2022

Xbrane provides update on ranibizumab biosimilar candidate FDA filing

30 Jun 2022

Xbrane Biopharma AB (“Xbrane” or the “Company”) announces changes to the number of shares and votes in the Company.

17 Jun 2022

Members of Xbrane’s management team sell shares to pay taxes but remain dedicated and long-term employees and shareholders

30 May 2022

Xbrane provides update on ranibizumab biosimilar candidate FDA filing

05 May 2022

Announcement from Xbrane Biopharma’s annual general meeting

05 May 2022

Xbrane Biopharma releases interim report for January – March 2022

02 May 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – March 2022 on May 5, 2022.

Financial Reports

18 Apr 2013

Annual report 2013 (available in Swedish only)

18 Apr 2014

Annual report 2014 (available in Swedish only)

31 Dec 2015

Annual report 2015 (available in Swedish only)

18 Dec 2015

Year-end report 2015 (available in Swedish only)

18 Apr 2015

Interim report January – September 2015 (available in Swedish only)

Financial Calendar

28 Oct 2022

Interim report January – September 2022

17 Feb 2023

Year-end report 2022

31 Mar 2023

Annual report 2022

04 May 2023

Annual General Meeting 2023

31 May 2023

Interim report January – March 2023

Contact Investor Relations

Anette Lindqvist, CFO & Head of Investor Relation

Presentations and media


PRESENTATION AT PARETO HELTHCARE CONFERENCE

September 3, 2020

Presentation at LSX Nordic Congress

August 29, 2019

Presentation at BioStock Live

March 20, 2019